AstraZeneca
  • Bookmark This Page
  • Print This Page
  • Share with a Friend
Change Text Size
Change Text Size
Change Text Size
Change Text Size
Change Text Size

Subscribe for additional information

AstraZeneca routinely sends information about PULMICORT RESPULES and the treatment of asthma-related symptoms. Please complete the questionnaire below to be included in these updates.

AstraZeneca respects that privacy is important to you. The information you provide may be used to send you health and product-related materials, to develop products, services, and programs that you may find useful, or to contact you. Please click here to review our Privacy Statement.

First Name*
Last Name*
E-mail*
Specialty*
Address
Address 2
City
State*
ZIP*

Yes, I would like to receive information in the future about all AstraZeneca products, programs and services that may be of interest to me.
Yes, I would like to receive e-mails notifying me when this site has been updated and when new information is available.

If you do not wish to receive more e-mail messages about PULMICORT RESPULES, please click here to unsubscribe.

Indication and Important Safety Information

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

[Please see accompanying full Prescribing Information (PDF).]